Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

News in the Life Sciences Industry
Results 421 - 440 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21 22  23  24  25 »
Reset  ↻

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Voyager Therapeutics, Inc.

Vistin Pharma ASA: Invitation to Q1 2024 conference call

Read more ››
By: GlobeNewswire - 16 Apr 2024

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Intra-Cellular Therapies, Inc.

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Clearside Biomedical, Inc.

St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Arch Biopartners, Inc.

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Eloxx Pharmaceuticals, Inc.

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Organogenesis Holdings Inc.

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Lexeo Therapeutics, Inc.

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  BioRestorative Therapies, Inc.

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Enlivex Therapeutics Ltd.

FountainRx Selects Inovalon’s ScriptMed® Software To Enhance Patient Care and Scale Specialty and Infusion Pharmacy Services

Read more ››
By: GlobeNewswire - 16 Apr 2024

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Certara USA, Inc. | Certara Australia | Certara

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Compass Therapeutics, Inc.

Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Vittoria Biotherapeutics, Inc.

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Monopar Therapeutics, Inc.

GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year

Read more ››
By: GlobeNewswire - 16 Apr 2024

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Daxor Corporation

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Recursion Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Read more ››
By: GlobeNewswire - 16 Apr 2024
Related companies:  Acumen Pharmaceuticals, Inc.

REPEAT – MEDIA ADVISORY: Press conferences with patients who have been charged user fees of hundreds or even thousands of dollars at for-profit surgery clinics

Read more ››
By: GlobeNewswire - 16 Apr 2024
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21 22  23  24  25 »
Terms of Use & Privacy Policy
to the top ↑